Amarin Corporation will announce Q3 2026 financial results on October 28, including a conference call for stakeholders.
Quiver AI Summary
Amarin Corporation plc will report its third quarter 2026 financial results on October 28, 2026, and will hold a conference call at 8:00 a.m. ET to discuss these results. A press release with the financial details will be issued before the market opens. Participants can join the call via phone or online, with specific dial-in numbers and access codes provided. Amarin promotes its flagship cardiovascular therapy, VASCEPA®, which has seen over 31 million prescriptions globally, and highlights its commitment to advancing cardiovascular disease prevention. The company encourages stakeholders to stay updated through its website and social media channels for further information and to access the replay of the call.
Potential Positives
- Amarin Corporation plans to report its third quarter 2026 financial results, indicating ongoing business operations and performance transparency to investors.
- The company’s flagship therapy, VASCEPA®, is a market leader, having been prescribed over 31 million times globally, demonstrating strong product acceptance and patient reliance.
- The upcoming conference call provides an opportunity for direct engagement between the company's senior management and investors, enhancing investor relations and transparency.
- Amarin actively encourages investors and the public to stay informed through its multiple communication channels, reinforcing its commitment to regular updates and transparency.
Potential Negatives
- Announcement of upcoming financial results may indicate concerns about previous performance, potentially signaling to investors that there could be negative trends in the company's financial health.
FAQ
When will Amarin report its third quarter 2026 financial results?
Amarin will report its third quarter 2026 financial results on Wednesday, October 28, 2026.
What time is the conference call for the financial results?
The conference call will take place at 8:00 a.m. ET on October 28, 2026.
How can I access the live conference call?
You can access the live call by dialing 888-506-0062 in the U.S. or 973-528-0011 internationally.
Where can I find the replay of the conference call?
A replay of the conference call will be available on Amarin's Investor Relations website shortly after the call.
What is VASCEPA and its significance?
VASCEPA is Amarin's flagship therapy for cardiovascular disease prevention, leading the U.S. market with over 31 million prescriptions globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRN Hedge Fund Activity
We have seen 34 institutional investors add shares of $AMRN stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 240,761 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,837,730
- MILLENNIUM MANAGEMENT LLC removed 184,728 shares (-61.5%) from their portfolio in Q2 2026, for an estimated $2,944,564
- BROOKLANDS FUND MANAGEMENT LTD added 177,325 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,826,560
- ACADIAN ASSET MANAGEMENT LLC added 84,215 shares (+13.2%) to their portfolio in Q2 2026, for an estimated $1,342,387
- MORGAN STANLEY removed 69,555 shares (-23.7%) from their portfolio in Q2 2026, for an estimated $1,108,706
- KYNAM CAPITAL MANAGEMENT, LP added 60,600 shares (+12.8%) to their portfolio in Q2 2026, for an estimated $965,964
- JANE STREET GROUP, LLC added 37,628 shares (+inf%) to their portfolio in Q2 2026, for an estimated $599,790
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026. The Company will issue a press release detailing its third quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.
Information on how to participate is as follows.
Access to the live call:
Via telephone: Dial in within the United States: 888-506-0062
International dial in: 973-528-0011
Access Code: 314562
Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at www.amarincorp.com.
Access to the replay:
Via telephone: Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Replay Code:54490
Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at www.amarincorp.com , beginning shortly after the end of the live call and available until 4/28/27.
About Amarin
At the Heart
of Amarin Corporation is a singular focus on advancing cardiovascular disease prevention worldwide. Our flagship oral prescription therapy, VASCEPA
®
(icosapent ethyl or IPE), is the U.S. market leader across all available IPE products and has been prescribed more than 31 million times globally. Through our independent U.S. commercial operations and global commercial partnerships, Amarin supports access to VASCEPA/VAZKEPA
®
across nearly 100 markets worldwide. For more information, visit
www.amarincorp.com
and follow Amarin on LinkedIn, X, Facebook. To be added to the Company's email list and receive news directly, please visit
https://investors.amarincorp.com/email-alerts
.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (
www.amarincorp.com
) and the investor relations website (
http://www.amarincorp.com/investor-relations
), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Media Inquiries:
Amarin Corporation plc
[email protected]
Investor Inquiries:
Devin Sullivan & Conor Rodriguez
The Equity Group on Behalf of Amarin
[email protected]
or
[email protected]
[email protected]
